US 11529427
Gene editing for hemophilia A with improved factor VIII expression
granted A61KA61K48/005A61K48/0058
Quick answer
US patent 11529427 (Gene editing for hemophilia A with improved factor VIII expression) held by CRISPR THERAPEUTICS AG expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K48/005, A61K48/0058, A61K48/0066, A61K48/0075